Arcutis Biotherapeutics, a biopharmaceutical company specializing in immuno-dermatology, announced it will present at the Guggenheim 3rd Annual Healthcare Innovation Conference from November 9-11, 2026, in Boston. The presentation will include a fireside chat on November 10, with a webcast available on the company's website. This event highlights Arcutis' ongoing commitment to innovation in treating chronic inflammatory skin diseases and provides an opportunity to showcase its latest developments and pipeline progress to investors and industry stakeholders.
Arcutis Biotherapeutics is presenting at the Guggenheim 3rd Annual Healthcare Innovation Conference. For readers following the health sector, here is Pluang's market snapshot as of Oct 28, 2026 02:21 WIB: Out of 150 priced US health stocks, 88 rose and 62 fell. Notable movers include TXG (10X Genomics Inc) at USD 78.42 with a 7.48% increase, CLPT (ClearPoint Neuro Inc) at USD 9.69 up 7.19% with 100% buy order activity, and RXRX (Recursion Pharmaceuticals Inc) at USD 4.07 rising 7.11% but with 99% sell order activity.
Vallourec will publish its Q3 2026 financial results on November 20, 2026, at 07:30 AM CET. The company's CEO Philippe Guillemot and CFO Nathalie Delbreuve will present the results via a conference call and webcast at 09:30 AM CET the same day. Inves...
MyPropCapital Technology Limited has launched a new trading evaluation platform that uses the Arbitrum One blockchain to record all fees, rules, passes, and rewards publicly. This system allows traders to verify every detail of their trading deals wi...
The European Central Bank (ECB) has confirmed KBC Group's minimum capital requirements for 2026 following its Supervisory Review and Evaluation Process (SREP). KBC must maintain a fully loaded CET1 ratio of 10.94%, which includes various regulatory b...
Bitget Wallet introduced Virtual Account, allowing users to open free USD and EUR accounts within their self-custodial crypto wallet, powered by licensed partner Noah. Funds deposited convert automatically to stablecoins like USDT or USDC, usable for...
The European Central Bank (ECB) has confirmed KBC Group's minimum capital requirements for 2026, maintaining the Pillar 2 Requirement at 1.95% and Pillar 2 Guidance at 1.00%. This results in an overall CET1 capital requirement of 10.94%. As of Q2 202...
